Novel 5-hydroxytryptamine (5-HT3) receptor antagonists. I. Synthesis and structure-activity relationships of conformationally restricted fused imidazole derivatives

Chemical and Pharmaceutical Bulletin

Volumn 44, Issue 5, 1996, Pages 991-999

  Ohta, Mitsuaki ^a   Suzuki, Takeshi ^a   Koide, Tokuo ^a   Matsuhisa, Akira ^a   Furuya, Toshio ^a   Miyata, Keiji ^a   Yanagisawa, Isao ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

5 HT3 receptor antagonist; irritable bowel syndrome; structure activity relationship; tetrahydrobenzimidazole; vomiting

Indexed keywords

4,5,6,7 TETRAHYDRO N (2 METHOXYPHENYL) 1H BENZIMIDAZOLE 5 CARBOXAMIDE; IMIDAZOLE DERIVATIVE; ONDANSETRON; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; COLON; DRUG CONFORMATION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; NAUSEA; STRUCTURE ACTIVITY RELATION; VOMITING;

EID: 0029899763     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.44.991     Document Type: Article

References (42)

1. a) Bradley P. B., Engel G., Feniuk W., Fozard J. R., Humphrey P. P. A., Middlemis D., Mylecharane E. J., Richardson B. P., Saxena P. R., Neuropharmacology, 25, 563-576 (1986);
2. b) Hoyer D., Clarke D. E., Fozard J. R., Hartig P. R., Martin G. R., Mylecharane E. J., Saxena P. R., Humpherey P. P. A., Pharmacol. Rev., 46, 157-203 (1994).
3. a) Yakel J. L., Jackson M. B., Neuron, 1, 615-621 (1988);
4. b) Derkach V., Surprenant A., North R. A., Nature, 339, 706-709 (1989).
5. a) Fozard J. R., Neuropharmacology, 23, 1473-1486 (1984);
6. b) Waeber C., Hoyer D., Palacios J. M., Neurosience, 31, 393-400 (1989);
7. c) Bobker D. H., Williams J. T., Trends Neurosci., 13, 169-173 (1990).
8. a) Sanger G. J., King F. D., Drug Design and Delivery, 3, 273-295 (1988);
9. b) King F. D., Sanger G. J., Drugs Future, 14, 875-889 (1989);
10. c) Kilpatrick G. J., Bunce K. T., Tyers M. B., Med. Res. Rev., 10, 441-475 (1990).
11. Butler A., Hill J. M., Ireland S. J., Jordan C. C., Tyers M. B., Br. J. Pharmacol., 94 (Suppl), 397-412 (1988).
12. Sanger G. J., Nelson D. R., Eur. J. Pharmacol., 159, 113-124 (1989).
13. Buchheit K. H., Engel G., Mutschler E., Richardson B., NaunynSchmiedeberg's Arch. Pharmacol., 329, 36-41 (1985).
14. a) Butler A., Elswood C. J., Burridge J., Ireland S. J., Bunce K. T., Kilpatrick G. J., Tyer M. B., Br. J. Pharmacol., 101, 591-598 (1990).
15. b) Miyata K., Kamato T., Mishida A., Ito H., Katsuyama Y., Iwai A., Yuki H., Yamano M., Tsutsumi R., Ohta M., Takeda M., Honda K., J. Pharmacol. Exp. Ther., 259, 15-21 (1991).
16. Miyata K., Kamato T., Nishida A., Ito H., Yuki H., Yamano M., Tsutsumi R., Katsuyama Y., Honda K., J. Pharmacol. Exp. Ther., 261, 297-303 (1992).
17. Thompson W. C., Gut, 25, 305-320 (1984).
18. Narducci F., Snape W. J., Battle W. M., London R. L., Cohen S., Dig. Dis. Sci., 30, 40-44, (1985).
19. a) Steadman C. J., Talley N. J., Phillips S. F., Mulvihill C., Gastroenterology, 98, A394 (1990);
20. b) Maxton D. G., Haigh C. G., Whorwell P. J., ibid., 100, A468 (1991).
21. a) Schmidt A. W., Peroutka S. J., Molecular Pharmacology, 36, 505-511 (1989);
22. b) Hibert M. F., Hoffmann R., Miller R. C., Carr A. A., J. Med. Chem., 33, 1594-1600 (1990);
23. c) Evans S. M., Galdes A., Gallm M., Pharmacol. Biachem. Behav., 40, 1033-1040 (1991).
24. Bermudez J., Fake C. S., Joiner G. F., Joiner K. A., King F. D., Miner W. D., Sanger G. J., J. Med. Chem., 33, 1924-1929 (1989).
25. Bermudez J., Dabbs S., King F. D., J. Med. Chem., 33, 1932-1935 (1989).
26. Oxford A. W., Bell J. A., Kilpatrick G. J., Ireland S. J., Tyers M. B., Prog. Med. Chem., 29, 239-270 (1992).
27. Oxford A. W., Cavalla D. J., European Patent 242973 (1988), [Chem. Abstr., 108, 112457p (1988)].
28. Turner R. A., Huebuner C. F., Scholz C. R., J. Am. Chem. Soc., 71, 2801-2803 (1949).
29. Vitali T., Mossini F., Berteccini G., Farmaco. Ed. Sci., 22, 821-845 (1967).
30. As a HCl salt; Butula I., Croat. Chem. Acta, 45, 297-312 (1973).
31. Brown L. J., Gude C., Rodriguez H., Steele R. E., J. Med. Chem., 34, 725-736 (1991).
32. As a free base; Schmidt G., Zeiler H. J., Metzger K. G., German Patent 3508258 A1 (1988) [Chem. Abstr., 108, 84274p (1988)].
33. Langlois Y., Potier P., Tetrahedron, 31, 419-422 (1975).
34. Ellis G. P., Jones R. T., J. Chem. Soc., Perkin Trans., 1, 1974, 903-909.
35. Blancy F. E., Clark M. S., Gardner D. V., Hadley M. S., Middleton D., White T. J., J. Med. Chem., 26, 1747-1752 (1983).
36. Details will be reported in a later paper.
37. a) Fozard J. R., Host M., Br. J. Pharmacol., 77, 520p (1982);
38. b) Miyata K., Kamato T., Yamano M., Mishida A., Ito H., Katsuyama Y., Yuki H., Tsutsumi R., Ohta M., Takeda M., Honda K., J. Pharmacol. Exp. Ther., 259, 815-819 (1991).
39. Bermudez J., King F. D., Sanger G. J., Bioorg. Med. Chem. Lett., 2, 1509-1512 (1992).
40. a) Itoh H., Hidaka K., Miyata K., Kamato T., Nishida A., Honda K., J. Pharmacol. Exp. Ther., 263, 1127-1132 (1992);
41. b) Miyake A., Mochizuki S., Takemoto Y., Akuzawa S., Molecular Pharmacol., 48, 407-416 (1995);
42. Kishibayashi N., Miwa Y., Hayashi H., Ishii A., Ichikawa S., Nonaka H., Yokoyama T., Suzuki F., J. Med. Chem., 36, 3286-3292 (1993).